-
Mashup Score: 1
Section:Current standard of care (SOC) for nonmetastatic TNM stage III-IV (except T3N0) nasopharyngeal carcinoma (NPC) is concurrent chemoradiotherapy (CCRT) plus induction or adjuvant chemotherapy (IC/AC).1 However, this is a heterogeneous group of patients, with the prognosis of early-stage III NPC being closer to that of stage II disease,2 whereas T4 and N3 tumors have distinctly poorer…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Our findings suggest that camrelizumab plus gemcitabine and cisplatin could be a new standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma in the first-line setting. Longer follow-up is needed to confirm this conclusion.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma - Annals of Surgical Oncology - 3 year(s) ago
Background Approximately 10% of patients with nasopharyngeal carcinoma (NPC) develop lung-only metastases. Data regarding the potential role of lung metastasectomy are limited. Objective The aim of this case-control study was to determine whether lung metastasectomy prolongs survival in patients with NPC with lung-only metastases. Methods The resectability of 215 consecutive patients diagnosed…
Source: Annals of Surgical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
Our findings suggest that camrelizumab plus gemcitabine and cisplatin could be a new standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma in the first-line setting. Longer follow-up is needed to confirm this conclusion.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4JUPITER-02: PD-1 Inhibitor Toripalimab Boosts Efficacy When Added to Standard First-Line Chemotherapy for Advanced Nasopharyngeal Carcinoma - 3 year(s) ago
The addition of toripalimab, a humanized IgG4ĸ monoclonal antibody targeting PD-1, to first-line gemcitabine/cisplatin followed by toripalimab maintenance succeeded in improving all efficacy endpoints compared with gemcitabine/cisplatin alone among patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) within the randomized, placebo-controlled, phase III JUPITER-02 trial (LBA2).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma - 3 year(s) ago
Background Approximately 10% of patients with nasopharyngeal carcinoma (NPC) develop lung-only metastases. Data regarding the potential role of lung metastasectomy are limited. Objective The aim of this case-control study was to determine whether lung metastasectomy prolongs survival in patients with NPC with lung-only metastases. Methods The resectability of 215 consecutive patients diagnosed…
Source: Annals of Surgical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics - 3 year(s) ago
Nasopharyngeal carcinoma (NPC) is a malignant cancer type with high morbidity in Asia, and its current molecular classification is insufficient to predict therapy outcomes. Here the authors explore NPC subtype-specific response to therapy with a pharmacogenomics strategy integrating genomics and drug response of patient-derived organoids.
Source: Nature CommunicationsCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4Capecitabine Maintenance Therapy Improves Progression-Free Survival in Metastatic Nasopharyngeal Carcinoma - 3 year(s) ago
Capecitabine maintenance therapy yielded significantly improved progression-free survival (PFS) compared with best supportive care (BSC) for patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC), while also showing low-grade and manageable toxicity, according to a new study (Abstract 6044).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
📣 #JCO #Editorial Identifying Patients with ‘Low-risk’ Locoregionally Advanced #NasopharyngealCarcinoma by Plasma EBV DNA for Chemotherapy De-intensification: Quo Vadis? https://t.co/dbY3X87lfJ #hncsm https://t.co/9lx6ttCx35